Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures

The NCI-60 cell line set is likely the most molecularly profiled set of human tumor cell lines in the world. However, a critical missing component of previous analyses has been the inability to place the massive amounts of “-omic” data in the context of functional protein signaling networks, which often contain many of the drug targets for new targeted therapeutics. We used reverse-phase protein array (RPPA) analysis to measure the activation/phosphorylation state of 135 proteins, with a total analysis of nearly 200 key protein isoforms involved in cell proliferation, survival, migration, adhesion, etc., in all 60 cell lines. We aggregated the signaling data into biochemical modules of interconnected kinase substrates for 6 key cancer signaling pathways: AKT, mTOR, EGF receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), integrin, and apoptosis signaling. The net activation state of these protein network modules was correlated to available individual protein, phosphoprotein, mutational, metabolomic, miRNA, transcriptional, and drug sensitivity data. Pathway activation mapping identified reproducible and distinct signaling cohorts that transcended organ-type distinctions. Direct correlations with the protein network modules involved largely protein phosphorylation data but we also identified direct correlations of signaling networks with metabolites, miRNA, and DNA data. The integration of protein activation measurements into biochemically interconnected modules provided a novel means to align the functional protein architecture with multiple “-omic” data sets and therapeutic response correlations. This approach may provide a deeper understanding of how cellular biochemistry defines therapeutic response. Such “-omic” portraits could inform rational anticancer agent screenings and drive personalized therapeutic approaches. Mol Cancer Res; 11(6); 676–85. ©2013 AACR.

[1]  A. Gaur,et al.  MicroRNA‐204/211 alters epithelial physiology , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[3]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[4]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[5]  M. Sudol,et al.  YAP: At the crossroad between transformation and tumor suppression , 2009, Cell cycle.

[6]  E. Petricoin,et al.  The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia , 2012, Haematologica.

[7]  Salam A. Assi,et al.  Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding , 2012, Leukemia.

[8]  James H Doroshow,et al.  Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines , 2010, Molecular Cancer Therapeutics.

[9]  Kevin Kontos,et al.  Information-Theoretic Inference of Large Transcriptional Regulatory Networks , 2007, EURASIP J. Bioinform. Syst. Biol..

[10]  E. Sausville,et al.  Transcription profiling of gene expression in drug discovery and development: the NCI experience. , 2004, European journal of cancer.

[11]  Frank Emmert-Streib,et al.  Inferring the conservative causal core of gene regulatory networks , 2010, BMC Systems Biology.

[12]  J. Collins,et al.  Large-Scale Mapping and Validation of Escherichia coli Transcriptional Regulation from a Compendium of Expression Profiles , 2007, PLoS biology.

[13]  E. Petricoin,et al.  Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. , 2011, Journal of proteome research.

[14]  S. Yang,et al.  Akt Phosphorylates MstI and Prevents Its Proteolytic Activation, Blocking FOXO3 Phosphorylation and Nuclear Translocation* , 2007, Journal of Biological Chemistry.

[15]  Jun-bing Wu,et al.  The c-Abl-MST1 Signaling Pathway Mediates Oxidative Stress-Induced Neuronal Cell Death , 2011, The Journal of Neuroscience.

[16]  S. Yonehara,et al.  Identification of Mechanism That Couples Multisite Phosphorylation of Yes-associated Protein (YAP) with Transcriptional Coactivation and Regulation of Apoptosis , 2012, The Journal of Biological Chemistry.

[17]  P. Geurts,et al.  Inferring Regulatory Networks from Expression Data Using Tree-Based Methods , 2010, PloS one.

[18]  J N Weinstein,et al.  A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.

[19]  B. Shi,et al.  MiR‐17‐92 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells , 2012, Journal of cellular biochemistry.

[20]  Kenichi Sugihara,et al.  Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters , 2012, Clinical Cancer Research.

[21]  E. Petricoin,et al.  Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. , 2012, Clinical colorectal cancer.

[22]  Q. Zeng,et al.  The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. , 2008, Cancer cell.

[23]  M. Lübbert,et al.  The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO , 2011, Oncogene.

[24]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[25]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Y. Hata,et al.  Mammalian Hippo pathway: from development to cancer and beyond. , 2011, Journal of biochemistry.

[27]  P. Ling,et al.  Biosignaling of mammalian Ste20-related kinases. , 2008, Cellular signalling.

[28]  H. Woo,et al.  Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set , 2010, Molecular Cancer Therapeutics.

[29]  Chris T. A. Evelo,et al.  Presenting and exploring biological pathways with PathVisio , 2008, BMC Bioinformatics.

[30]  R. Broaddus,et al.  PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. , 2012 .

[31]  P. Yelick,et al.  The pro‐apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1 , 2007, The EMBO journal.

[32]  Jie Yang,et al.  MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8 , 2011, Oncogene.

[33]  Chris Wiggins,et al.  ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context , 2004, BMC Bioinformatics.

[34]  P. Sharp,et al.  MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. , 2011, Blood.